MedTrace Logo

Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

NCT07440901 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-02-27

No results posted yet for this study

Summary

In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.

Conditions

  • Muscle-invasive Bladder Cancer

Interventions

DRUG

Immunotherapy plus chemotherapy

The neoadjuvant therapy regimen for muscle-invasive bladder cancer is the GC regimen. This study does not alter the patients' neoadjuvant therapy regimen but adds toripalimab to the selected neoadjuvant treatment. After MDT discussion, eligible patients will receive GC combined with immunotherapy therapy.

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Xiongjun Ye · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-05-15
Completion
2027-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07440901 on ClinicalTrials.gov